View ValuationWerewolf Therapeutics 将来の成長Future 基準チェック /06Werewolf Therapeuticsの収益は年間10.8%で減少すると予測されていますが、年間収益は年間64.5%で増加すると予想されています。EPS は年間3.1%で増加すると予想されています。主要情報-10.8%収益成長率3.13%EPS成長率Biotechs 収益成長22.9%収益成長率64.5%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日17 Apr 2026今後の成長に関する最新情報Price target decreased by 18% to US$5.20 Dec 19Price target decreased by 12% to US$6.33 Nov 10Price target decreased by 8.9% to US$6.83 Sep 03Price target decreased by 12% to US$8.33 Aug 04Price target decreased by 11% to US$10.67 Jan 14Consensus revenue estimates decrease by 45%, EPS upgraded Nov 14すべての更新を表示Recent updatesWerewolf Therapeutics, Inc. Announces Executive Changes, Effective February 13, 2026Feb 14+ 2 more updatesWerewolf Therapeutics Receives Notice of Nasdaq Bid Price Deficiency and Listing Compliance PeriodFeb 07New major risk - Share price stability Jan 23Price target decreased by 18% to US$5.20 Dec 19New major risk - Share price stability Dec 19Price target decreased by 12% to US$6.33 Nov 10Werewolf Therapeutics, Inc. Presents Data Expanding Its Predator®? Platform At the Society for Immunotherapy of Cancer's (Sitc) 40Th Annual MeetingNov 07Werewolf Therapeutics, Inc. Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of CancerOct 10Werewolf Therapeutics Announces Board Member's Passing Causes Temporary Nasdaq Audit Committee Non-ComplianceOct 07Price target decreased by 8.9% to US$6.83 Sep 03Price target decreased by 12% to US$8.33 Aug 04Werewolf Therapeutics, Inc. Receives Nasdaq Non-Compliance Notice Regarding Bid Price DeficiencyMay 16First quarter 2025 earnings released: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024) May 09Werewolf Therapeutics Presents New Preclinical Data Further Characterizing Its Il-10 Indukine Molecule, Wtx-921, for the Treatment of Inflammatory Bowel Disease At AAI Annual MeetingMay 06Werewolf Therapeutics, Inc., Annual General Meeting, Jun 12, 2025Apr 29Werewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApr 17New minor risk - Share price stability Apr 09Full year 2024 earnings: EPS misses analyst expectations Mar 11Werewolf Therapeutics, Inc. Announces Board ChangesFeb 24Price target decreased by 11% to US$10.67 Jan 14Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?Nov 14Consensus revenue estimates decrease by 45%, EPS upgraded Nov 14New minor risk - Revenue size Nov 08Third quarter 2024 earnings released: US$0.38 loss per share (vs US$0.23 loss in 3Q 2023) Nov 08Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNov 08Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a First-Of-Its-Kind IL-10 INDUKINE Molecule for Inflammatory DiseasesOct 31Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1 Jul 01Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaJun 25Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% PoundingJun 04Insufficient new directors Jun 02Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingMay 24Consensus revenue estimates fall by 68% May 10First quarter 2024 earnings: EPS and revenues miss analyst expectations May 04Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual MeetingApr 24Werewolf Therapeutics, Inc., Annual General Meeting, May 24, 2024Apr 13Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space Apr 04Consensus EPS estimates upgraded to US$1.24 loss Mar 14Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 08Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift TooFeb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price RiseDec 09Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 17Price target increased by 7.9% to US$12.80 Nov 07Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNov 04Werewolf Therapeutics, Inc. to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's 38th Annual MeetingNov 01New major risk - Share price stability Oct 24Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) EstimatesSep 30Consensus revenue estimates increase by 30% Sep 29New major risk - Share price stability Aug 24Consensus revenue estimates decrease by 23%, EPS upgraded Aug 17Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAug 13New minor risk - Market cap size Jun 28Consensus revenue estimates increase by 71% Jun 07Consensus revenue estimates decrease by 57%, EPS upgraded May 18We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash WiselyMay 06Price target decreased by 8.1% to US$13.66 Feb 12Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth PlansJan 27Price target decreased to US$14.86 Dec 06Consensus revenue estimates increase by 117% Nov 17Werewolf Therapeutics Presents Preclinical Data on mWTX-330, A Surrogate IL-12 Indukine™ Molecule, at the Society for Immunotherapy of Cancer Annual MeetingNov 11We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn RateOct 24Werewolf Therapeutics, Inc. Announces Initiation of Patient Dosing in Phase 1/1B Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid TumorsSep 02We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash WiselyJul 08Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) dropped from Russell 2500 Value IndexJun 26+ 2 more updatesHigh number of new directors Apr 27Werewolf Therapeutics, Inc., Annual General Meeting, Jun 01, 2022Apr 23High number of new directors Apr 20Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual MeetingApr 09Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth PlansMar 24Chief Scientific Officer exercised options to buy US$354k worth of stock. Jan 16High number of new directors Dec 31Chief Operating Officer notifies of intention to sell stock Dec 21Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth PlansDec 09Werewolf Therapeutics, Inc. has completed an IPO in the amount of $120 million.May 01業績と収益の成長予測NasdaqGS:HOWL - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20280-125-32N/A212/31/2027N/A-104-50N/A212/31/2026N/A-68-46N/A212/31/2025N/A-61-60-60N/A9/30/2025N/A-73-64-64N/A6/30/2025N/A-73-61-61N/A3/31/20251-72-60-60N/A12/31/20242-71-56-56N/A9/30/20243-62-47-47N/A6/30/20249-54-42-41N/A3/31/202416-42-39-38N/A12/31/202320-37-33-33N/A9/30/202326-37-41-40N/A6/30/202325-41-50-47N/A3/31/202321-50-40-37N/A12/31/202216-54-44-41N/A9/30/20229-60-45-41N/A6/30/20224-62-41-39N/A3/31/2022N/A-115-50-50N/A12/31/2021N/A-202-43-43N/A9/30/2021N/A-205-36-36N/A6/30/2021N/A-197-29-29N/A3/31/2021N/A-127-23-23N/A12/31/2020N/A-28-19-19N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HOWL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: HOWL今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: HOWL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: HOWL来年は収益がないと予測されています。高い収益成長: HOWL来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HOWLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/01 00:35終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Werewolf Therapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Jason ZemanskyBofA Global ResearchManeka MirchandaneyEvercore ISIAndres MaldonadoH.C. Wainwright & Co.5 その他のアナリストを表示
Werewolf Therapeutics, Inc. Announces Executive Changes, Effective February 13, 2026Feb 14+ 2 more updates
Werewolf Therapeutics Receives Notice of Nasdaq Bid Price Deficiency and Listing Compliance PeriodFeb 07
Werewolf Therapeutics, Inc. Presents Data Expanding Its Predator®? Platform At the Society for Immunotherapy of Cancer's (Sitc) 40Th Annual MeetingNov 07
Werewolf Therapeutics, Inc. Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of CancerOct 10
Werewolf Therapeutics Announces Board Member's Passing Causes Temporary Nasdaq Audit Committee Non-ComplianceOct 07
Werewolf Therapeutics, Inc. Receives Nasdaq Non-Compliance Notice Regarding Bid Price DeficiencyMay 16
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing Its Il-10 Indukine Molecule, Wtx-921, for the Treatment of Inflammatory Bowel Disease At AAI Annual MeetingMay 06
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNov 08
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a First-Of-Its-Kind IL-10 INDUKINE Molecule for Inflammatory DiseasesOct 31
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaJun 25
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% PoundingJun 04
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingMay 24
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual MeetingApr 24
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift TooFeb 07
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price RiseDec 09
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNov 04
Werewolf Therapeutics, Inc. to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's 38th Annual MeetingNov 01
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) EstimatesSep 30
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAug 13
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, A Surrogate IL-12 Indukine™ Molecule, at the Society for Immunotherapy of Cancer Annual MeetingNov 11
Werewolf Therapeutics, Inc. Announces Initiation of Patient Dosing in Phase 1/1B Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid TumorsSep 02
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) dropped from Russell 2500 Value IndexJun 26+ 2 more updates
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual MeetingApr 09